When to Bring in an Interim VP of Regulatory Affairs

Medical-device companies rarely struggle because no one is working hard enough.

They struggle because the regulatory decisions being made are bigger than the experience, authority, or available time of the people currently making them.

A growing company may have a talented regulatory manager, a capable quality leader, an experienced consultant, and a strong engineering team. Yet no one is consistently connecting product strategy, clinical evidence, design controls, testing, submissions, manufacturing readiness, and executive priorities into one regulatory plan.

That is the point where additional tactical support may not be enough.

The company may need executive regulatory leadership—but not necessarily a permanent full-time hire.

An Interim Vice President of Regulatory Affairs can provide senior-level direction during a critical development stage, submission, remediation effort, financing event, acquisition, leadership gap, or international expansion. The role is typically time-limited, outcome-focused, and designed around a defined business need.

The right interim leader does more than prepare documents.

They help the company make better decisions before those decisions become expensive.

What Does an Interim VP of Regulatory Affairs Actually Do?

An Interim VP of Regulatory Affairs temporarily assumes responsibility for the company’s regulatory strategy, leadership, and execution.

Depending on the organization, the role may include:

• Defining the U.S. and international regulatory pathway

• Leading FDA 510(k), De Novo, PMA, IDE, or Pre-Submission strategy

• Evaluating product classifications and predicates

• Aligning testing with regulatory objectives

• Reviewing design-control and risk-management documentation

• Managing FDA interactions and deficiency responses

• Coordinating regulatory consultants and testing laboratories

• Building or mentoring the internal regulatory team

• Supporting investor, board, and due-diligence discussions

• Preparing the company for a permanent regulatory executive

• Identifying risks that could affect timelines, budgets, or valuation

The position sits between strategy and execution.

A consultant may provide an opinion or prepare a specific deliverable. A regulatory manager may maintain documentation and coordinate submissions. An Interim VP is expected to own the broader outcome, challenge assumptions, prioritize risks, and communicate directly with senior leadership.

Sign 1: Regulatory Decisions Are Being Made Too Late

One of the clearest warning signs is that regulatory affairs is routinely brought into the conversation after major development decisions have already been made.

Examples include:

• The product design is nearly frozen before the predicate is selected.

• Mechanical testing begins before acceptance criteria are justified.

• Marketing claims are drafted before the indications for use are finalized.

• A manufacturing process changes after verification without a regulatory impact assessment.

• Clinical data are collected without confirming that the endpoints support the intended claim.

• A submission is assembled after the evidence package is already complete.

At that stage, regulatory affairs is no longer guiding the program. It is being asked to explain decisions made elsewhere.

An Interim VP can reposition regulatory strategy earlier in the process and create formal decision points before design freeze, testing, validation, labeling approval, and submission.

Sign 2: Your Submission Is Technically Active but Strategically Unclear

Many submissions move forward without a concise, defensible answer to basic questions:

• What is the regulatory pathway?

• Why is the predicate appropriate?

• What are the key technological differences?

• Which tests address those differences?

• What are the acceptance criteria?

• What is the worst-case configuration?

• What evidence is still missing?

• What could cause FDA to reject the current approach?

When different team members give different answers, the company has a leadership problem—not merely a documentation problem.

An Interim VP can establish one regulatory narrative and align the submission team around it. That includes engineering, quality, clinical, manufacturing, marketing, external consultants, and executive leadership.

The value is not simply better writing.

It is preventing the organization from pursuing several conflicting strategies at once.

Sign 3: FDA Questions Keep Revealing Deeper Problems

An Additional Information request may contain dozens of questions, but those questions often point to only a few underlying issues:

• Weak predicate strategy

• Inadequate performance benchmarks

• Poor worst-case justification

• Inconsistent device descriptions

• Unsupported labeling claims

• Incomplete risk controls

• Testing that does not represent the final device

• Insufficient manufacturing or validation evidence

Companies sometimes respond to each question individually without addressing the larger pattern. This can lead to longer responses, repeated questions, new inconsistencies, and a declining level of reviewer confidence.

An Interim VP can step back from the wording of the request and identify what FDA is actually concerned about. They can then determine whether the right response is additional explanation, new analysis, supplemental testing, a design change, narrower indications, or a revised regulatory strategy.

More words are not always the answer.

Sometimes the company needs a different plan.

Sign 4: The Regulatory Team Is Capable but Overextended

A company does not need to have a weak regulatory team to benefit from interim leadership.

In fact, many organizations seek an Interim VP because the existing team is competent but stretched across too many responsibilities:

• Maintaining registrations and listings

• Reviewing product changes

• Supporting design controls

• Preparing international submissions

• Managing labeling

• Responding to complaints

• Participating in audits

• Coordinating testing

• Writing a major FDA submission

• Supporting commercial and investor requests

A strong regulatory manager may be fully capable of executing the work but lack the time, executive authority, or board-level access to resolve cross-functional issues.

An Interim VP can provide air cover, prioritize the portfolio, negotiate realistic timelines, and escalate decisions that should not remain buried in working-level meetings.

The goal should be to strengthen the internal team—not replace it.

Sign 5: No One Owns the Regulatory Portfolio

As companies grow, regulatory projects often become scattered across departments.

One submission is owned by engineering. Another is managed by a consultant. International registrations sit with quality. Product changes are reviewed informally. Post-market commitments are stored in spreadsheets. Leadership receives updates only when something goes wrong.

This creates hidden risk.

The company may not have a consolidated view of:

• Submission status

• Regulatory commitments

• Upcoming renewals

• Testing dependencies

• Unresolved FDA questions

• Product-change assessments

• International registration obligations

• Labeling updates

• Post-market requirements

• Regulatory spending

An Interim VP can establish portfolio-level governance, including priorities, owners, milestones, risks, decision logs, and executive reporting.

For a company with multiple products, the ability to decide what not to pursue can be as valuable as moving the highest-priority submission forward.

Sign 6: The Company Is Preparing for Financing, Acquisition, or Due Diligence

Regulatory weakness becomes much more visible during a financing event, licensing discussion, strategic partnership, or acquisition.

Investors and buyers will want to understand:

• Whether the regulatory pathway is credible

• Whether submission timelines are realistic

• Whether testing supports the product claims

• Whether correspondence with FDA reveals unresolved risk

• Whether quality-system records support the regulatory strategy

• Whether international registrations are current

• Whether product changes were properly assessed

• Whether key approvals depend on a single consultant or employee

• Whether the company has underestimated future regulatory costs

An experienced Interim VP can prepare the company for this scrutiny, identify gaps before they are discovered by the other side, and explain regulatory risk in a balanced and commercially intelligent way.

This does not mean presenting every issue as insignificant.

It means showing that the company understands its risks, has credible mitigation plans, and is not surprised by its own regulatory history.

Sign 7: Your Consultant Network Is Producing Advice, but No Unified Strategy

Specialized consultants can be extremely valuable.

A company may use separate experts for:

• FDA strategy

• Biocompatibility

• Sterilization

• Software

• Human factors

• Clinical affairs

• Statistical analysis

• Mechanical testing

• International registrations

• Quality-system remediation

The difficulty is that each consultant usually sees only part of the program.

One recommendation may conflict with another. Testing may be scientifically sound but poorly connected to the predicate strategy. A clinical consultant may recommend a study that exceeds what is necessary for the intended submission. A laboratory may propose familiar tests without defining the regulatory purpose of each one.

Without internal executive ownership, the company can become the project manager for a collection of disconnected opinions.

An Interim VP can coordinate these specialists, determine which recommendations serve the actual business objective, and ensure that external advisors are working from the same device description and regulatory strategy.

Sign 8: Leadership Cannot Get a Straight Answer on Timeline or Risk

Executives do not need every regulatory detail.

They do need reliable answers to questions such as:

• When can we submit?

• What must happen first?

• What is the critical path?

• Which assumptions are uncertain?

• What is the probability of a major delay?

• What additional testing might be required?

• Which decisions need executive approval?

• What is the expected regulatory spend?

• What would cause us to change direction?

When regulatory updates are either overly optimistic or buried in technical detail, leadership cannot make sound business decisions.

An Interim VP translates regulatory complexity into decision-ready information. That includes distinguishing between:

• Internal target dates and realistic dates

• Known requirements and assumptions

• Manageable risks and program-threatening risks

• Required testing and optional evidence

• FDA review time and total time to clearance

• Regulatory milestones and commercial readiness

Good executive communication is not about making uncertainty disappear.

It is about making uncertainty visible and manageable.

Sign 9: The Company Is Entering a New Market or Regulatory Pathway

A team experienced with U.S. Class II 510(k) devices may not be prepared to lead:

• A De Novo request

• A PMA program

• An IDE study

• A combination product

• EU MDR certification

• Canadian licensing under MDSAP

• Australian, Japanese, or Brazilian market entry

• A software-heavy or connected device

• A novel implant with limited predicate options

New pathways introduce different evidence standards, review dynamics, timelines, and business risks.

An Interim VP with relevant experience can help the company determine whether the proposed market is commercially justified, what organizational capabilities are missing, and whether the product strategy should be modified before significant spending begins.

Sign 10: You Need a Permanent VP, but You Are Not Ready to Hire One

Hiring a full-time regulatory executive can take months.

The company may also be unsure what profile it actually needs.

Should the permanent leader be strongest in:

• U.S. submissions?

• International market access?

• Clinical strategy?

• Regulatory operations?

• Quality systems?

• Combination products?

• Software?

• Orthopedic or spine devices?

• Team building?

• Public-company communication?

An Interim VP can stabilize the function while helping define the permanent role. They can assess the team, document the regulatory portfolio, establish processes, resolve urgent issues, and participate in candidate evaluation.

This creates a more orderly transition and reduces the risk of hiring someone into a poorly defined position with unrealistic expectations.

When an Interim VP May Not Be Necessary

Not every company needs executive-level interim support.

A more limited consultant or project manager may be sufficient when:

• The regulatory pathway is established.

• The submission is routine and well supported.

• Internal leadership is experienced and available.

• The company needs only a specific technical deliverable.

• Cross-functional alignment is already strong.

• The project does not carry significant strategic or financial risk.

The distinction comes down to ownership.

When the company needs a defined document, a specialist may be enough.

When it needs someone to make, defend, coordinate, and communicate high-impact regulatory decisions, executive leadership is usually required.

What Should the Engagement Look Like?

An effective interim engagement should be built around measurable outcomes.

Possible objectives include:

• Complete a regulatory portfolio assessment

• Confirm the product pathway and predicate strategy

• Create an integrated evidence plan

• Prepare or recover a 510(k) submission

• Lead an FDA Additional Information response

• Prepare for a Pre-Submission meeting

• Establish regulatory governance

• Remediate design-control or submission gaps

• Prepare for investor or acquisition due diligence

• Build and mentor the regulatory team

• Recruit and transition to a permanent VP

The engagement should also define:

• Decision authority

• Executive sponsor

• Internal team responsibilities

• Meeting cadence

• Deliverables

• Timeline

• Budget authority

• Use of outside consultants

• Reporting expectations

• Exit and transition plan

Without clear authority, an interim executive can quickly become another advisor whose recommendations are discussed but not implemented.

What to Look for in an Interim Regulatory Leader

The ideal person is not simply the candidate with the most submissions.

Look for someone who can:

• Understand the technology quickly

• Identify the most important regulatory risks

• Challenge unsupported assumptions

• Communicate with engineers and executives

• Connect testing to substantial equivalence

• Write clearly and persuasively

• Manage FDA interactions professionally

• Build systems rather than create dependency

• Make decisions with incomplete information

• Balance compliance, timing, cost, and commercial objectives

• Leave the internal organization stronger than they found it

Industry-specific experience matters, particularly for complex implants, software, combination products, or novel technologies. But leadership ability is equally important.

The role requires both technical judgment and organizational influence.

The Cost of Waiting Too Long

Companies often delay bringing in senior regulatory leadership because they view it as an added expense.

That comparison is usually incomplete.

The real comparison is between the cost of interim leadership and the cost of:

• Repeating mechanical or validation testing

• Redesigning after a failed submission

• Delaying a product launch

• Missing financing milestones

• Losing distributor confidence

• Extending consultant engagements

• Responding to avoidable FDA deficiencies

• Discovering compliance gaps during due diligence

• Hiring the wrong permanent executive

• Diverting engineering resources into regulatory recovery

A project-based executive can be expensive by the hour and inexpensive by the outcome.

The earlier the person is engaged, the more opportunity they have to prevent problems rather than explain them.

A Practical Readiness Test

Your company may be ready for an Interim VP of Regulatory Affairs when several of the following are true:

• A major submission or FDA interaction is approaching.

• Regulatory decisions are affecting financing or commercialization.

• The current team lacks bandwidth or executive authority.

• Product development and regulatory strategy are not fully aligned.

• Outside consultants are not working from one coordinated plan.

• FDA questions are exposing systemic gaps.

• Leadership lacks clear visibility into regulatory risk.

• The company is entering a new market or pathway.

• A permanent executive search is underway.

• Delays would materially affect company value.

The greater the business consequence of a regulatory mistake, the stronger the case for executive-level ownership.

Interim Leadership Should Create Lasting Capability

The best Interim VP does not become indispensable.

They establish priorities, resolve urgent issues, transfer knowledge, mentor the team, improve decision-making, and create a regulatory structure the company can sustain.

At the end of the engagement, the organization should have:

• A clearer regulatory strategy

• Better portfolio visibility

• Stronger internal leadership

• More defensible timelines

• Better-controlled external consultants

• Improved executive communication

• A credible transition plan

• Fewer unresolved surprises

Interim leadership is not simply a temporary replacement for an open position.

Used correctly, it is a focused way to add the level of experience the company needs at the exact point when the regulatory and business stakes are highest.

Does Your Company Need Interim Regulatory Leadership?

Texas BioVentures provides project-based executive regulatory leadership for spine, orthopedic, and medical-device companies navigating submissions, FDA interactions, product-development challenges, quality-system gaps, due diligence, and organizational transitions.

Engagements can be structured around a specific submission, a defined regulatory milestone, a portfolio assessment, or temporary leadership of the regulatory function.

This article is provided for general informational purposes and does not constitute legal or regulatory advice.